MA68585A1 - Acide nucléique ayant une activité de promoteur et son utilisation - Google Patents

Acide nucléique ayant une activité de promoteur et son utilisation

Info

Publication number
MA68585A1
MA68585A1 MA68585A MA68585A MA68585A1 MA 68585 A1 MA68585 A1 MA 68585A1 MA 68585 A MA68585 A MA 68585A MA 68585 A MA68585 A MA 68585A MA 68585 A1 MA68585 A1 MA 68585A1
Authority
MA
Morocco
Prior art keywords
nucleic acid
promoter activity
relates
present
genetics
Prior art date
Application number
MA68585A
Other languages
English (en)
Inventor
Pavel Andreevich IAKOVLEV
Dmitry Valentinovich MOROZOV
Anna Nikolaevna STRELKOVA
Mariya Pavlovna PEREPELKINA
Pavel Mikhailovich GERSHOVICH
Elena Veniaminovna VLASOVA
Konstantin Ilich TYSHCHUK
Original Assignee
Joint Stock Company "Biocad"
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from RU2022115853A external-priority patent/RU2818112C2/ru
Application filed by Joint Stock Company "Biocad" filed Critical Joint Stock Company "Biocad"
Publication of MA68585A1 publication Critical patent/MA68585A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
    • A61K48/0041—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being polymeric
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43595—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from coelenteratae, e.g. medusae
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/60—Fusion polypeptide containing spectroscopic/fluorescent detection, e.g. green fluorescent protein [GFP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/34—Vector systems having a special element relevant for transcription being a transcription initiation element

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La présente invention concerne les domaines de la génétique, de la thérapie génique et de la biologie moléculaire. Plus spécifiquement, la présente invention concerne un acide nucléique ayant une activité de promoteur (variantes), une cassette d'expression et un vecteur basé sur celle-ci, une cellule hôte pour produire un produit cible ou un vecteur d'expression.
MA68585A 2022-06-10 2023-06-11 Acide nucléique ayant une activité de promoteur et son utilisation MA68585A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
RU2022115853A RU2818112C2 (ru) 2022-06-10 Нуклеиновая кислота, имеющая промоторную активность, и ее применение
PCT/RU2023/050148 WO2023239267A1 (fr) 2022-06-10 2023-06-11 Acide nucléique ayant une activité de promoteur et son utilisation

Publications (1)

Publication Number Publication Date
MA68585A1 true MA68585A1 (fr) 2025-04-30

Family

ID=89039587

Family Applications (1)

Application Number Title Priority Date Filing Date
MA68585A MA68585A1 (fr) 2022-06-10 2023-06-11 Acide nucléique ayant une activité de promoteur et son utilisation

Country Status (20)

Country Link
US (1) US20250281640A1 (fr)
EP (1) EP4536837A1 (fr)
JP (1) JP2025519357A (fr)
KR (1) KR20250022710A (fr)
CN (1) CN117210457A (fr)
AR (1) AR129552A1 (fr)
AU (1) AU2023285585A1 (fr)
CA (1) CA3252733A1 (fr)
CL (1) CL2024003742A1 (fr)
CO (1) CO2024016864A2 (fr)
CR (1) CR20240561A (fr)
IL (1) IL316991A (fr)
JO (1) JOP20240270A1 (fr)
MA (1) MA68585A1 (fr)
MX (1) MX2024015099A (fr)
PE (1) PE20251263A1 (fr)
PY (1) PY2342670A (fr)
TW (1) TW202413647A (fr)
UY (1) UY40304A (fr)
WO (1) WO2023239267A1 (fr)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021209574A1 (fr) * 2020-04-15 2021-10-21 Fondazione Telethon Constructions comprenant des intéines

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10611837B2 (en) * 2014-04-10 2020-04-07 Seattle Children's Hospital Transgene genetic tags and methods of use
CN107073051B (zh) * 2014-10-21 2021-08-24 马萨诸塞大学 重组aav变体及其用途
LT3277807T (lt) * 2015-03-31 2020-01-10 Glycotope Gmbh Eukariotiniai ekspresijos vektoriai, apimantys globino genų klasterių reguliavimo elementus
RU2742837C1 (ru) * 2020-06-02 2021-02-11 Общество С Ограниченной Ответственностью "Анабион" Кодон-оптимизированная нуклеиновая кислота, которая кодирует белок SMN1, и ее применение
RU2760301C1 (ru) * 2020-12-21 2021-11-23 Закрытое Акционерное Общество "Биокад" Вакцина на основе AAV5 для индукции специфического иммунитета к вирусу SARS-CoV-2 и/или профилактики коронавирусной инфекции, вызванной SARS-CoV-2

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021209574A1 (fr) * 2020-04-15 2021-10-21 Fondazione Telethon Constructions comprenant des intéines

Also Published As

Publication number Publication date
WO2023239267A1 (fr) 2023-12-14
TW202413647A (zh) 2024-04-01
JOP20240270A1 (ar) 2024-12-05
CL2024003742A1 (es) 2025-04-11
AR129552A1 (es) 2024-09-04
AU2023285585A1 (en) 2024-11-21
CA3252733A1 (fr) 2023-12-14
EP4536837A1 (fr) 2025-04-16
KR20250022710A (ko) 2025-02-17
PY2342670A (es) 2023-12-19
UY40304A (es) 2023-12-29
CO2024016864A2 (es) 2025-02-24
CN117210457A (zh) 2023-12-12
US20250281640A1 (en) 2025-09-11
MX2024015099A (es) 2025-01-09
CR20240561A (es) 2025-05-05
JP2025519357A (ja) 2025-06-26
IL316991A (en) 2025-01-01
PE20251263A1 (es) 2025-05-07

Similar Documents

Publication Publication Date Title
Santos et al. Structural and functional properties of ras proteins
Kotelevets et al. Rac1 signaling: from intestinal homeostasis to colorectal cancer metastasis
Bastounis et al. Subendothelial stiffness alters endothelial cell traction force generation while exerting a minimal effect on the transcriptome
Hirst et al. Characterization of a fourth adaptor-related protein complex
Koong et al. Targeting XBP-1 as a novel anti-cancer strategy
Rahman et al. Functions and mechanisms of protein disulfide isomerase family in cancer emergence
AU2016342380B2 (en) Nucleobase editors and uses thereof
Peng et al. Disruption of the Diaphanous-related formin Drf1 gene encoding mDia1 reveals a role for Drf3 as an effector for Cdc42
Somanna et al. Functional Analysis of Cathepsin B-like Cysteine Proteases fromLeishmania donovani Complex: Evidence for the activation of latent transforming growth factor β
Stuart et al. Mitochondrial DNA of kinetoplastids
Lanzaro et al. Microsatellite DNA and isozyme variability in a West African population of Anopheles gambiae
Shih et al. Collapsin response mediator protein-1: a novel invasion-suppressor gene
Sun et al. Filamin-A regulates neutrophil uropod retraction through RhoA during chemotaxis
Taheri et al. Leishmania-based expression systems
MA62178A1 (fr) Effet synergique de smn1 et mir-23a dans le traitement de l'amyotrophie spinale
ATE293633T1 (de) Hypoxie-regulierte gene
Oda et al. Multi-forms of human MTH1 polypeptides produced by alternative translation initiation and single nucleotide polymorphism
Sato et al. Two cysteine protease inhibitors, EhICP1 and 2, localized in distinct compartments, negatively regulate secretion in Entamoeba histolytica
Nyström et al. Virus-induced transcriptional activation of host FUT genes associated with neo-expression of Ley in cytomegalovirus-infected and sialyl-Lex in varicella-zoster virus-infected diploid human cells
MA68585A1 (fr) Acide nucléique ayant une activité de promoteur et son utilisation
Kandalaft et al. Differentially expressed nucleolar transforming growth factor-β1 target (DENTT) exhibits an inhibitory role on tumorigenesis
Khier et al. Molecular cloning and characterization of the mouse histone deacetylase 1 gene: integration of a retrovirus in 129SV mice
Fischer et al. Loss of a newly discovered microRNA in Chinese hamster ovary cells leads to upregulation of N‐glycolylneuraminic acid sialylation on monoclonal antibodies
Pandey et al. Ancestral TALE homeobox protein transcription factor regulates actin dynamics and cellular activities of protozoan parasite Entamoeba invadens
MA68435A1 (fr) Acide nucléique isolé codant pour une protéine de fusion à base de fviii-bdd et d'un peptide de signal hétérologue